What is the potential of biotherapeutics in GCC countries?
The objective of this joint venture is to capitalise on each other’s strengths – Biocon’s technical know-how and Neopharma’s prowess to manufacture and market biopharmaceutical products in the GCC Region. The potential would of course depend on the type of product mix. Biopharmaceuticals in the area of chronic therapy conditions such as diabetes, cardiovascular disorders etc hold good potential. Besides presence in oncology and rheumatoid arthritis are also important For the patients here, it would mean quality lifesaving medicines manufactured right here in the heart of the Emirates. Further, manufacturing of critical products can help maintain stocks of life saving drugs locally and therefore minimize the chances of any import delays and higher prices. How far the ongoing Dubai Biotechnology and Research Park (DuBiotech) project could help UAE to become self sufficient in the innovative discipline of biotechnology? What is the current status? By establishing DuBiotech, the country’s
